Paper
0
Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
Authors
Fabrice André,Eva Ciruelos
Gábor Rubovszky,Mario Campone,Sibylle Loibl,Hope Rugo,Hiroji Iwata,Pierfranco Conté,Ingrid Mayer,Bella Kaufman,Toshinari Yamashita,Yen‐Shen Lu,Kenichi Inoue,Masato Takahashi,Zsuzsanna Pápai,Anne-Sophie Longin,César Boguszewski,Celine Wilke,Samit Hirawat,Dejan Juric
+18 authors
,David MillsPublished
May 15, 2019
Show more
Save
Tip0
TipSave
Abstract
PIK3CA mutations occur in approximately 40% of patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer. The PI3Kα-specific inhibitor alpelisib has shown antitumor activity in early studies.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.